The first interim efficacy analysis of Phase 2/3 clinical trial evaluating Pfizer and BioNTech’s Covid-19 vaccine candidate showed it to be more than 90% effective seven days after the second dose in preventing infection in participants with no evidence of prior SARS-CoV-2 infection. An emergency use authorization (EUA) application will be made after the required safety milestone is achieved, expected to occur in the third week of November.
Click here for the full Trefis coverage of Pfizer
- Pfizer Vaccine Updates: Possibly Easier Storage, Efficacy Against South African Strain
- Forecast of the Day: Pfizer’s Immunology Drugs Revenue
- Buy Pfizer Stock Or JNJ For Vaccine Run?
- What The Approval Of The Covid Vaccine In The U.K Means For Pfizer Stock
- Here’s Why Pfizer Stock Looks Inviting At $39 Levels
- Why Pfizer’s Covid-19 Vaccine Is Unlikely To Move The Needle For The Stock
Looking for a balanced portfolio to invest in? Here’s a high-quality portfolio to beat the market, with over 100% return since 2016, versus 55% for the S&P 500. Comprised of companies with strong revenue growth, healthy profits, lots of cash, and low risk, it has outperformed the broader market year after year, consistently.
See all Trefis Price Estimates and Download Trefis Data here
What’s behind Trefis? See How It’s Powering New Collaboration and What-Ifs For CFOs and Finance Teams | Product, R&D, and Marketing Teams
